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Nasal continuous positive airway pressure (nCPAP) is the current treatment of obstructive sleep apnoea syndrome 
(OSAS). The indications of bilevel pressure support ventilation (BIPAP PSV) in OSAS patients remain controver- 
sial. The purpose of this investigation was to verify the frequency of prescription of BIPAP PSV in a group of OSAS 
patients when CPAP was ineffective or not tolerated during titration. The study included 286 consecutive patients 
2 18 years of age referred to two Sleep laboratories for sleep related breathing disorders (SRBD) between December 
1994 and November 1995. Of these, 130 patients were enrolled and 105 (88 males, 77 females) with moderate to 
severe OSAS completed the study and were finally analysed. After a full night diagnostic polysomnography (PSG,), 
patients had a second full night PSG under nCPAP (PSG,). If nCPAP was not tolerated, or failed to correct 
breathing abnormalities during sleep, a second PSG, was performed, using a BIPAP PSV. 
Our study shows that nCPAP (mean 8.5 * 2.0 cmH,O) was considered a satisfactory therapy in 81 patients (77%). 
Twenty four (23%) required BIPAP PSV (mean IPAP 13.9 & 2.9 cmH,O). We found the highest prevalence of BIPAP 
in patients with OSAS associated to obesity hypoventilation syndrome (OHS) (11 of 17) and in OSAS associated to 
chronic obstructive pulmonary disease (COPD) (nine of 16). Patients treated with BIPAP PSV were more obese and 
had a higher PaCO, and sleep-related desaturations and a lower FEVl, FVC, FEVZIFVC and PaO,. In conclusion 
our study shows that CPAP therapy is the effective therapeutic option in the majority of patients with OSAS. There 
is a subset of patients with OSAS associated to COPD or to OHS in whom BIPAP PSV may be a better treatment 
modality. 
RESPIR. MED. (1998) 92, 820-827 
Introduction 
Obstructive sleep apnoea syndrome (OSAS) is character- 
ized by intermittent and recurrent upper airway collapse 
during sleep. Nasal continuous positive airway pressure 
(nCPAP) is an effective means of achieving pharyngeal 
patency by pneumatic splinting of the collapsible segment 
thereby preventing obstructive apnoeas (1,2) and it is 
current standard treatment of obstructive sleep apnoea. 
However, in other sleep related breathing dis- 
orders (SRBD) without upper airway obstruction (central 
sleep apnoea, primary and secondary hypoventilation) 
nCPAP is usually not effective. Moreover some OSAS 
patients may not tolerate nCPAP due to impairment of 
Received 23 June 1997 and accepted in revised form 12 January 
1998. 
Correspondence should be addressed to: Dr R. Onofrio, Via 
Manzoni 11, 70010 Turi, Bari, Italy. 
0954-6111/98/060820+08 $12.00/O 
expiration (3). In these patients the increased work of 
breathing required to complete expiration against a positive 
pressure resulted in a sensation of dyspnoea and/or discom- 
fort (4,5), which may be sufficient to disturb sleep. In OSAS 
in which high pressure during nCPAP is necessary but not 
tolerated, or in OSAS accompanied by persistent sleep- 
related hypoventilation, nCPAP may be ineffective and 
other modalities of pressure support ventilation may offer 
advantages over nCPAP (3). The BiPAP S/Ta device 
(airway management system Respironics, Inc., Murrisville, 
PA, U.S.A.) produces independently adjusted inspiratory 
and expiratory positive airway pressure and has been 
demonstrated to be effective in management of OSAS, even 
when expiratory pressures are substantially lower than 
those required during CPAP therapy (6). The possibility of 
delivering two pressure levels with a lower expiratory 
pressure decreased the work of breathing and may increase 
the acceptance and the compliance of nightly treatment in 
OSAS. 
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However, the indication of bilevel pressure support 
ventilation (BIPAP PSV) in OSAS patients remains 
controversial (3,7,8). 
We assessed a group of 105 Italian OSAS patients for 
the use of prescription BIPAP PSV when nCPAP was 
ineffective or was not tolerated during titration. 
Materials and methods 
STUDY SUBJECTS 
The study population consisted of 286 consecutive patients 
2 18 years of age referred for SRBD to sleep laboratories of 
the Respiratory Disease Institute of Sacco Hospital in 
Milan and of the Department of Respiratory Disease of the 
University of Bari, Italy, between December 1994 and 
November 1995. 
One hundred and thirty patients were recruited according 
to the following criteria: 
(1) an apnoea and hypopnoea index (AHI) of at least ten 
events h - ’ of sleep with at least 80% obstructive events 
during laboratory full night diagnostic polysomnogra- 
phy (PSG,), with habitual snoring (identified when 
subjects reported snoring always or almost always) and 
excessive daytime sleepiness (identified when subjects 
reported feeling excessively sleepy always or almost 
always); 
(2) no hormonal or major psychiatric diseases or renal 
failure requiring dialysis or class 34 heart failure; 
(3) absence of acute respiratory tract infection or acute 
exacerbation or chronic obstructive pulmonary disease 
(COPD); 
(4) no previous surgical approach for OSAS or ventilatory 
treatment; 
(5) sufficient patency of nose; 
(6) no alcohol, hypnotic and psychotropic drug 
dependence; 
(7) no hypnotic, psychotropic or theophilline treatment in 
the study period. 
Although the subjects were recruited from two different 
centres, they have been treated as a single sample. Further- 
more there were no substantial differences between the two 
groups in parameters likely to influence the results: the 
patients of Milan Centre were older (age 54.X * 7 vs 
51.1 i 3 years) and showed more airways obstruction 
(FEVl/FVC% 76.1 f 3 vs 78.1 z!= 2). 
PROTOCOL 
All subjects with SRBD, on admission to hospital and 
before initiating the first PSG, underwent the clinical 
(pneumological, cardiological, neurological, endocrinologi- 
cal, and ENT examinations) and laboratory evaluations, a 
validated sleep questionnaire, conventional spirography, 
anthropometric and arterial blood gas measurements and 
chest radiograph. The polysomnography was made after a 
night of habituation. All OSAS patients enrolled on the 
basis of inclusion criteria underwent, within a two-week 
period from the first PSG,, a second polysomnography 
during which titration of nCPAP was attempted (PSG,). If 
CPAP failed (see further), the patients were prescribed a 
trial with BIPAP PSV within two weeks of the nCPAP 
titration night. Before PSG, the patients controlled the 
respiratory function, arterial blood gas and body mass 
index (BMI) measurements, and received training to 
become familiar with the nasal mask and BIPAP device. 
The nCPAP was started at 2 cmH,O and pressure was 
increased by increments of 2 cmH,O every 30 mins until 
snoring, apnoeas and hypopnoeas were eliminated in all 
sleep stages, including REM stage and in the supine 
position. The therapeutic nCPAP pressure was titrated 
to eliminate snoring and all obstructive apnoeas and 
hypopnoeas and to preserve sleep continuity without 
arousals and awakenings. 
nCPAP was considered inappropriate if patients were 
intolerant of the pressure with impairment of sleep conti- 
nuity; if apnoeas persisted despite the use of high pressure; 
if correction of apnoeas occurred without correction of 
significant nocturnal hypoventilation. The BIPAP PSV 
titration was made as follows: initially inspiratory (IPAP) 
and expiratory (EPAP) pressures were set at 2 cmH,O and 
were increased by 2 cmH,O, modifying EPAP to eliminate 
apnoeas and IPAP to eliminate desaturation events not 
accompanied by apnoeas (non-apnoeic desaturation 
events), snoring and hypoventilation if present (8). For 
both forms of therapy the nCPAP and BIPAP PSV pressure 
was increased if three or more sleep disordered breathing 
events occurred in a 30-min interval. The hypoventila- 
tion was assessed by overnight monitoring of arterial 0, 
saturation and arterial blood CO, tensions (PaCO,). 
If necessary (when significant oxygen desaturation 
persisted after eliminating apnoeas and hypopnoeas) sup- 
plementary oxygen varying from 0.5 to 2 1 mini was 
added to a port in the nasal mask to maintain the nocturnal 
SaO, above 85%90%. Chin straps were used to minimize 
mouth leaks and ensure effective pressure was not lost. The 
determination of effective nCPAP or BIPAP PSV was 
made by each sleep centre physician during the night and 
computer analysed with automatic and manual editing. 
The same protocol was approved by both institutions’ 
committees. All subjects gave their informed consent to the 
study. 
MEASUREMENT OF SRBD 
Polysomnography was performed by Vitalog HMS 5000 
(Vitalog monitoring INC) and the Healthdyne Alice III 
System. We recorded electroencephalogram (EEG), electro- 
oculogram (EOG), chin electromyogram (EMG), electro- 
cardiogram (ECG) with surface electrodes, nasal and oral 
air flow by thermocouples, ribcage and abdominal move- 
ments with inductive plethysmography, oxyhaemoglobin 
saturation by finger pulse oxymetry, sleeping position and 
snoring. 
An obstructive apnoea was defined as the absence of 
inspiratory airflow for more than 10 s during continued 
efforts to breathe; hypopnoea as the decrease in inspiratory 
flow of 50% with persistent respiratory effort plus a 4% 
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drop in oxyhaemoglobin saturation from the pre- 
hypopnoeic level. We recorded apnoea plus hypopnoea 
index per h of sleep (AHI), minimum nocturnal oxy- 
haemoglobin saturation (Nadir SaO, %), mean nocturnal 
oxyhaemoglobin saturation (mean SaO, %). 
Hypoventilation was defined as persistent reduced flow at 
the nose and/or a reduction in 0, saturation not resulting in 
sleep fragmentation (9-12). 
Arterial blood PaCO, measurement was performed 
during PSG, in patients with COPD and obesity hypo- 
ventilation syndrome (OHS) and with nocturnal hypo- 
ventilation. In 80% of these patients an indwelling radial 
catheter was inserted, in 20% multiple arterial blood 
samples were made. The arterial blood gas analyses were 
performed prior to the start of PSG during wakefulness 
with the patient in the supine position and later during sleep 
at least 3 h after sleep onset, during REM stage, at maxi- 
mum ventilatory pressure and when the persistent and 
significant desaturation period not associated to events 
occurred. 
During PSG,, according to Piper et al. (13) we consid- 
ered as acceptable a rise in PaCO, less than 7 mmHg, with 
respect to awake supine values. 
Polysomnographic techniques and interpretation con- 
formed with standards set by the American Sleep Disorders 
Association. 
We used BIPAP ST Respironics Inc to deliver nCPAP or 
bilevel PSV. 
DATA ANALYSIS 
All data are reported as mean + SD. Results for groups 
of patients treated by CPAP and BIPAP (CPAP group 
and BIPAP group) were compared using Student’s t-test for 
unpaired data. We also used x2 test for comparison 
of proportions in independent samples. We also used 
Pearson’s random single regression analysis to evaluate the 
relationship between variables. In all statistical tests a P 
value of 0.05 was accepted as the level of significance. 
Results 
Of 286 consecutive patients referred for SRBD, 130 (45%) 
patients with OSAS were initially enrolled, but 25 were 
excluded after the enrolment. Of these patients, 12 were 
excluded because they refused to undergo ventilatory treat- 
ment due to discomfort of the mask, seven patients because 
they did not tolerate either nCPAP nor nBIPAP PSV 
treatment, and six patients did not complete the protocol 
and were lost from the study. 
The results of the remaining 105 patients (88 males and 
17 females) were finally analysed and form the substance 
of the present report. However, there were no systematic 
or statistically significant differences between subjects 
excluded and subjects included in the results. 
The mean values of morphometric, respiratory function 
and polysomnographic data of the 105 patients who com- 
pleted the study are shown in Table 1. A marked obesity 
with a BMI>35kgmp2 was present in 48 of the 105 
patients (46%). Twenty five patients had a sirometric result 
suggestive of a restrictive defect (FVC<80% with a normal 
FEVIIFVC): 24 of these patients had obesity as the only 
explanation; one patient had a fibrothorax. At presentation 
13 of the 105 patients (12%) had PaO, less than 65 mmHg 
(8.6 kPa); 26 patients (25%) were hypercapnic, (mean 
PaCO, 48 + 3.3 mmHg, 6.4 & 0.5 kPa, range 45-56 mmHg, 
6-7.5 kPa). 
We divided our OSAS population into four groups: (I) 
patients with simple OSAS, with BMIi35 kg m -’ (defined 
as OSAS); (2) OSAS with marked obesity with 
BMI> 35 kg rn-’ (defined as OB); (3) OSAS associated 
with COPD (defined as COPD), when there was a history of 
dyspnoea and chronic daily cough for more than 2 years 
preceding presentation, a history of cigarette smoking for 
20 yr or longer and in the presence of a FEV1<75% of 
predicted, a FEVI/FVC<70%, a flow volume loop com- 
patible with obstruction; (4) OSAS associated with OHS 
(defined as OHS) as evidenced by sleepiness, day-time 
hypercapnia (PaCO, 2 45 mmHg; 60 kPa) marked obesity 
(BMI 2 35 kg m ~ “) mild or absence of obstructive ventila- 
tory defect. The mean value of morphometric, respiratory 
function and polysomnographic data of the four groups are 
shown in Table 2. 
nCPAP (8.5 & 2.0 cmH,O, range 4-16) was considered as 
a correct therapy in 81 patients (77%) (CPAP group), 
according to the criteria of efficacy previously described. 
Of this group, 49% had simple OSAS, 19 had OB, seven 
presented with COPD (one had a PaCO,>45 mmHg; 
6.0 kPa) and six had OHS. Twenty-four of 105 (23%) of 
patients required BIPAP PSV (BlPAP group) Table 3. 
The mean inspiratory pressure was 13.9 * 2.9 cmH,O 
(range 8-18) and the mean expiratory pressure was 
7.6 & 2.2 cmH,O (range 5-12). BIPAP PSV was used in 
four patients (two OSAS and two OS) who developed 
central apnoeas that disturbed sleep continuity; seven 
patients were intolerant to high pressure levels of the CPAP 
with awakening, or mask leaks (five had COPD and two 
had OHS). In 11 patients (seven with OHS and four with 
COPD), we found during CPAP, periods of substantial 
desaturation poorly affected by 0, administration and 
with unacceptable CO, retention, with a mean rise with 
respect to awake values of 12 mmHg (1.6 kPa) (range 
8-16 mmHg); 1.1-2.1 kPa). In two patients (with OHS) 
multiple reasons necessitated the use of BIPAP. 
In the BIPAP group two patients had simple OSA, two 
had OB, nine had COPD (PaCO, 49.4 mmgH & 6.1, range 
46-56 kPa 6.6 f 0.8, range 67.1) 11 OHS (PaCO, 
47.5 mmHg rt 2.8 range 45-53 kPa 6.3 & 0.4 range 6-7). 
Table 4 shows the respective treatments in the different 
subgroups of patients: OSAS, OB, OHS and COPD. We 
found the highest prevalence of BIPAP treatment in 
patients with OHS (11 of 17 patients) and with COPD (nine 
of 16 patients). The X2-test disclosed a significant difference 
in the assignment of ventilatory treatments to the different 
subgroups. In the CPAP group there was a significant 
prevalence of patients with OSAS+OB (P<O.OOl) with 
respect to the patients with OHS + COPD (P<O,OO 1). In the 
BIPAP group there was prevalence of patients with 
OHS+COPD with respect to OSAS+OB (P<O.OOl). 
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TABLE 3. Results of polysomnographic data in CPAP group and BIPAP group 
CPA’ AND BIPAF IN OSAS 825 
CPAP group BIPAP group 
(n=78/81)~ (n=21/24)t 
Baseline Treatment P t-test Baseline Treatment P t-test 
AH1 (nh-‘) 45.9 3.5 *** 47 5 *** 
Mean SaO, % 87.4 93 *** 87 91.7 *** 
Nadir SaO, % 64 83 *** 61 85 *** 
ODI (nh-‘) 40.3 2.9 *** 50 5.7 *** 
P t-test (baseline vs treatment): *P<O.O5; **P<O.Ol; ***P<O.OOl. 
i-The patients of CPAP group and BIPAP group receiving nocturnal supplementary oxygen were 
omitted. 
In OHS and COPD patients of BIPAP group the mean 
overnight level of PaCO, fell significantly from 
57 & 7.8 mmHg (7.6 rt 1 kPa) during the CPAP treatment 
to 46.5 & 4 mmHg (6.2 & 0.5 kPa) during the BIPAP treat- 
ment. Awake value for these patients was 47 f 2 mmHg. 
The comparison between the two groups, CPAP and 
BIPAP, is shown in the Table 5. There was no difference in 
age, AH1 and Nadir SaO,%. Moreover, these results show 
that although AH1 was similar in two groups, ODI was 
significantly higher in the BIPAP group and this indicates 
in these patients the importance of non-apnoeic breathing 
disorders. Simple positive correlations were found in the 
CPAP group between therapeutic CPAP and BMI (r10.47; 
P<O.OOl) AH1 (r=0.45; P<O.OOl), ODI (r=0.44; P<O.OOl) 
and an inverse correlation between CPAP and Nadir SaO, 
(r= -0.31; P<O.OOl) and mean SaO,% (r= - 41; 
P<O.OOl). In the BIPAP group, IPAP pressure was signifi- 
cantly and inversely correlated to PaO, (Y= - 0.43; 
P<O.O5). The IPAP-EPAP pressure difference was 
significantly correlated to PaCO, (r=0.62; P<O.OOl). 
A single full night PSG was inadequate to meet criteria 
for therapeutic efficacy in six subjects with CPAP and three 
with BIPAP PSV because of inadequate sleep time (‘3 h) 
to allow pressure titration and an effective pressure was 
determined during subsequent full night polisomnography. 
All patients were initially ventilated with spontaneous (S) 
ventilatory mode. In four patients, BIPAP PSV had to be 
changed to the spontaneous/timed mode because of signifi- 
cant central apnoeas and in one patient to timed mode 
TABLE 4. Frequency of treatments in the different sub- 
groups of patients 
OSAS OB OHS COPD Total 
CPAP 49 19 6 7 81 
BIPAP 2 2 11 9 24 
Total 51 21 17 16 105 
x2 test: P<O.OOl; x2 (OSAS+OB vs OHS+COPD): 
P<O.OOl; x2 (OSA vs OB): P=n.s.; x2 (OHS vs COPD): 
P=n.s. 
because of irregular respiratory rate with hypoventilation. 
Seven subjects with a low basal awake PaO, required 
supplementary 0, during PSG, because of a low SaO, 
(~85%) during non-apnoeic/hypopnoeic events. Of these, 
six patients also required supplementary 0, during admin- 
istration of positive airway pressure (three during CPAP 
and three during BIPAP treatment). A chin strap was used 
in 25 patients to reduce oral leak. 
Discussion 
Although nasal CPAP therapy is effective for a majority of 
patients with OSAS its use may be limited in some patients. 
In this study we set out to determine the frequency of 
prescription of BIPAP during titration after CPAP failure 
in a group of 130 patients with OSAS, recruited from the 
subjects referred to two Italian sleep laboratories over a 
I-yr period. We found that 81 patients (62%) were satisfac- 
torily treated with CPAP. In 24 (18%) nCPAP was unsuc- 
cessful and BIPAP S/ST was an effective treatment 
modality. Twenty-five patients (19%) refused or were 
unable to use either type of device. 
There are few reports in the literature showing conflicting 
data about BIPAP and CPAP treatment in OSAS patients. 
Becker et al. (3) found that of 328 patients only 32 (10%) 
had to be treated with BIPAP, whereas Sanders et al. (14), 
in a selected group of 30 OSAS patients, reported that 14 
patients (46%) required BIPAP. The discrepancy of the 
results may depend on the different protocols utilized but 
also on the modality of the study (retrospective studies such 
as Becker and prospective studies such as Sanders and our 
study) and especially on the different characteristics of 
OSAS patients studied. In this regard our OSAS population 
was not representative of the general OSAS population. In 
fact it has been reported (15) that in a population of OSAS 
patients, about 20% constitute a special group (OSAS plus 
COPD, OSAS plus heart failure, OSAS plus OHS). In our 
population of 105 patients who completed the study and 
were finally analysed, the special group (so-called overlap 
syndromes) represented 3 1% (OSAS plus COPD-15%, 
OSAS plus OHS-16%) which is higher than the prevalence 
reported in the literature, so that the relatively large 
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TABLE 5. Comparison of 
and BIPAP group. Data 
morphometric, respiratory function and polysomnographic diagnostic parameters in CPAP group 
are mean f SD 
Parameters CPAP group 
n 81 
BIPAP group 
24 
P I-test 
CPAP group vs BIPAP group 
Age 52.5 f 12.4 54.0 It 8.9 n.s. 
BMI (kg m - “) 32.9 f 5.9 39.7 f 6.1 *** 
FEVl (%) 86.8 f 20.2 67.2 dz 24.9 *** 
FVC (%) 88.7 zt 17.9 73.8 zt 17.6 *** 
FEVUFVC (%) 79.1 Zt 10.1 72.2 zk 13.4 ** 
PaO, mmHg kPa mJfk kPa 
81.2 z!= 10.9 10.8 + 1.4 70.0 =L 10.4 9.3 It 1.3 *** 
PaCO, mmHg kPa mJ& kPa 
39.9 It 3.7 5.3 h 0.4 45.4 zk 5.84 6.1 & 0.7 *** 
AH1 (nh-‘) 46.9 zt 20.7 50.4 zlc 17.0 n.s. 
Mean SaO, (%) 89.4 I!= 5.9 86.5 zt 6.9 * 
Nadir SaO, (%) 68.4 z!z 12.6 64.1 zk 13.2 n.s. 
ODI (nh-‘) 39.5 h 19.2 51.9 f- 28.4 * 
proportion requiring BIPAP therapy may be explained by 
the higher prevalence of overlap syndromes. In fact if we 
consider only the subgroup of patients affected by OSAS 
and OSAS with marked obesity but without COPD and 
OHS, CPAP was effective and tolerated in 68 of 72 patients 
(94%). In the BIPAP group 83% were COPD and OHS and 
the majority (74%) were hypercapnic. 
The comparison of morphometric, pulmonary function 
and polysomnographic parameters in two groups (CPAP 
group and BIPAP group) shows that patients treated with 
BIPAP had a higher BMI and PaCO, and a lower PaO,, 
FEVl, FVC, FEVUFVC, and mean SaO,%. 
An associated airway disease is generally observed in 
about 10% of the OSAS population (16), which is lower 
than the prevalence of COPD in our patients (15%). 
In our study CPAP failed in nine of 16 COPD patients 
(56%) of whom seven were hypercapnic. It is known that 
some patients with COPD find expiration difficult and 
uncomfortable when EPAP is high and this may be suffi- 
cient to disturb sleep (17). A positive expiratory pressure 
may reduce the work of breathing but if it exceeds intrinsic 
positive end expiratory pressure, it will induce hyper- 
inflation and increase the elastic work of breathing (18). 
Furthermore, nocturnal hypoventilation is a recognized 
problem in COPD (19,20) and BIPAP PSV was as effective 
as intermittent positive pressure ventilation (IPPV) in 
reducing nocturnal hypercapnia in these patients (21). In 
COPD it was possible with BIPAP PSV, to reduce hyper- 
capnia and to maintain the upper airway patency at a lower 
level of EPAP compared with nCPAP, with better patient 
tolerance. 
In our patients the prevalence of OHS was also rather 
high (16%) and 11 of 16 required BIPAP PSV. Some 
authors (13) reported that patients with OHS have persist- 
ent non-apnoeic desaturations and impairment of ventila- 
tion even after the elimination of the occlusive apnoeas with 
CPAP. In many of these patients CPAP failed essentially 
because it could not avoid hypoventilation with excessive 
hypercapnia. In these patients in which apnoea and hypo- 
ventilation may coexist, BIPAP PSV maintains airway 
patency and improves or prevents nocturnal hypoventila- 
tion and subsequent hypercapnia. 
In the majority of our patients BIPAP PSV was utilized 
as pressure support (spontaneous mode). This suggests that 
our hypoventilating sleeping patients were able to trigger 
the ventilator and did so at an adequate rate throughout the 
night and that the problem in these patients is predomi- 
nantly of hypoventilation rather than apnoea. However, 
even using BIPAP PSV some patients required supplemen- 
tary oxygen to achieve acceptable levels of SaO,. In 
addition, recently Piper and Sullivan (13) have shown, in 
OHS patients with nocturnal associated hypoventilation 
and CO, retention, that after a initial CPAP failure and a 
period of some months of therapy with NIPPV, there could 
follow an improvement in blood gases and spontaneous 
ventilation that allowed these patients to become respond- 
ers to CPAP. Thus some of our patients with OSAS 
associated to OHS could be switched to CPAP in the 
future. 
A limitation in our study could be the lack of continuous 
CO, monitoring in a group of hypoventilating sleeping 
patients. In our study the PaCO, determinations were 
made on samples drawn from an indwelling radial arterial 
catheter during sleep in the majority of patients. In 20% it 
was not possible to insert a indwelling radial arterial 
catheter and we documented the hypoventilation by 
multiple arterial blood samples. Furthermore, the most 
appropriate and feasible technique for monitoring change 
in acid/base balance and PaCO, with acceptable accuracy 
during nocturnal ventilatory assistance, remains debatable 
and even if the transcutaneous and tidal CO, tension 
(PeTCO,) has been utilized in several studies, at the present 
time, uncertainties regarding the reliability of this non- 
invasive CO, monitoring suggest that overnight arterial 
blood gas sampling is advisable (22). Finally, concerning 
the protocol of the study, one may ask whether a single 
night of nCPAP failure is sufficient to declare nCPAP as 
inefficient, other groups required the nCPAP trial polysom- 
nography to be preceded by several nights habituation 
while still other groups advocate split-night studies, so that 
a firm consensus does not exist up to date. 
In conclusion, our study shows that CPAP therapy is an 
effective therapeutic option in the majority of patients with 
obstructive sleep apnoea, even if severe, and with normal 
awake respiratory function. There is however a subset of 
patients with OSAS associated to COPD or OHS, especially 
when hypercapnia is present in whom CPAP may be 
ineffective or not tolerated; bilevel PSV may initially be an 
effective and well-tolerated treatment modality for them. 
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